(ISRG) Intuitive Surgical - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 160.562m USD | Total Return: 1% in 12m

Surgical Systems, Endoluminal Systems, Instruments, Support, Digital
Total Rating 50
Safety 94
Buy Signal -0.64
Medical Instruments & Supplies
Industry Rotation: -7.6
Market Cap: 161B
Avg Turnover: 749M USD
ATR: 2.64%
Peers RS (IBD): 34.3
Risk 5d forecast
Volatility30.6%
Rel. Tail Risk-12.1%
Reward TTM
Sharpe Ratio0.02
Alpha-30.41
Character TTM
Beta0.918
Beta Downside0.450
Drawdowns 3y
Max DD29.63%
CAGR/Max DD0.71
EPS (Earnings per Share) EPS (Earnings per Share) of ISRG over the last years for every Quarter: "2021-03": 1.17, "2021-06": 1.31, "2021-09": 1.19, "2021-12": 1.3, "2022-03": 1.13, "2022-06": 1.14, "2022-09": 1.19, "2022-12": 1.23, "2023-03": 1.23, "2023-06": 1.42, "2023-09": 1.46, "2023-12": 1.6, "2024-03": 1.5, "2024-06": 1.78, "2024-09": 1.84, "2024-12": 2.21, "2025-03": 1.81, "2025-06": 2.19, "2025-09": 2.4, "2025-12": 2.53, "2026-03": 0,
EPS CAGR: -43.23%
EPS Trend: 14.9%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ISRG over the last years for every Quarter: 2021-03: 1292.1, 2021-06: 1464, 2021-09: 1403.3, 2021-12: 1550.7, 2022-03: 1487.7, 2022-06: 1522.1, 2022-09: 1557.4, 2022-12: 1655, 2023-03: 1696.2, 2023-06: 1755.9, 2023-09: 1743.7, 2023-12: 1928.3, 2024-03: 1890.6, 2024-06: 2009.9, 2024-09: 2038.1, 2024-12: 2413.5, 2025-03: 2253.4, 2025-06: 2440, 2025-09: 2505.1, 2025-12: 2866.2, 2026-03: null,
Rev. CAGR: 19.11%
Rev. Trend: 98.1%
Last SUE: 2.17
Qual. Beats: 6

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: ISRG Intuitive Surgical

Intuitive Surgical, Inc. (ISRG) develops and markets robotic surgical systems and instruments. Its primary product, the da Vinci Surgical System, facilitates minimally invasive surgeries. The company also offers the Ion endoluminal system for diagnostic lung biopsies. The medical device sector is characterized by high research and development costs and long product development cycles.

ISRGs business model includes selling surgical systems, instruments, and providing ongoing services. These services encompass installation, maintenance, technical support, and digital performance insights. The company utilizes a direct sales force for its products. Further research on platforms like ValueRay can provide deeper insights into ISRGs financial performance and market position.

Headlines to Watch Out For
  • da Vinci system sales drive revenue growth
  • Instrument and accessory sales boost recurring income
  • Ion system adoption expands diagnostic market share
  • Regulatory approvals impact new product launches
  • Hospital capital expenditure cycles affect system sales
Piotroski VR‑10 (Strict) 8.0
Net Income: 2.86b TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.15 > 1.0
NWC/Revenue: 77.23% < 20% (prev 64.24%; Δ 12.99% < -1%)
CFO/TA 0.15 > 3% & CFO 3.03b > Net Income 2.86b
Net Debt (-5.63b) to EBITDA (3.62b): -1.55 < 3
Current Ratio: 4.87 > 1.5 & < 3
Outstanding Shares: last quarter (360.4m) vs 12m ago -0.96% < -2%
Gross Margin: 66.00% > 18% (prev 0.67%; Δ 6.53k% > 0.5%)
Asset Turnover: 51.00% > 50% (prev 44.34%; Δ 6.66% > 0%)
Interest Coverage Ratio: 32.58 > 6 (EBITDA TTM 3.62b / Interest Expense TTM 90.4m)
Altman Z'' 7.34
A: 0.38 (Total Current Assets 9.78b - Total Current Liabilities 2.01b) / Total Assets 20.63b
B: 0.34 (Retained Earnings 7.01b / Total Assets 20.63b)
C: 0.15 (EBIT TTM 2.95b / Avg Total Assets 19.73b)
D: 2.62 (Book Value of Equity 7.06b / Total Liabilities 2.69b)
Altman-Z'' Score: 7.34 = AAA
Beneish M -3.03
DSRI: 1.00 (Receivables 1.63b/1.36b, Revenue 10.06b/8.35b)
GMI: 1.02 (GM 66.00% / 67.46%)
AQI: 0.72 (AQ_t 0.27 / AQ_t-1 0.37)
SGI: 1.21 (Revenue 10.06b / 8.35b)
TATA: -0.01 (NI 2.86b - CFO 3.03b) / TA 20.63b)
Beneish M-Score: -3.03 (Cap -4..+1) = AA
What is the price of ISRG shares? As of April 09, 2026, the stock is trading at USD 462.28 with a total of 2,224,246 shares traded.
Over the past week, the price has changed by -0.47%, over one month by -6.34%, over three months by -20.99% and over the past year by +1.02%.
Is ISRG a buy, sell or hold? Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.
  • StrongBuy: 14
  • Buy: 8
  • Hold: 10
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the ISRG price?
Analysts Target Price 605.1 30.9%
Intuitive Surgical (ISRG) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 57.4422
P/E Forward = 45.045
P/S = 15.9529
P/B = 9.0082
P/EG = 2.3256
Revenue TTM = 10.06b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 3.62b USD
Long Term Debt = 263.8m USD (estimated: total debt 302.8m - short term 39.0m)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.63b USD (recalculated: Debt 302.8m - CCE 5.93b)
Enterprise Value = 154.93b USD (160.56b + Debt 302.8m - CCE 5.93b)
Interest Coverage Ratio = 32.58 (Ebit TTM 2.95b / Interest Expense TTM 90.4m)
EV/FCF = 62.20x (Enterprise Value 154.93b / FCF TTM 2.49b)
FCF Yield = 1.61% (FCF TTM 2.49b / Enterprise Value 154.93b)
FCF Margin = 24.75% (FCF TTM 2.49b / Revenue TTM 10.06b)
Net Margin = 28.38% (Net Income TTM 2.86b / Revenue TTM 10.06b)
Gross Margin = 66.00% ((Revenue TTM 10.06b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 66.44% (prev 66.36%)
Tobins Q-Ratio = 7.51 (Enterprise Value 154.93b / Total Assets 20.63b)
Interest Expense / Debt = 29.85% (Interest Expense 90.4m / Debt 302.8m)
Taxrate = 16.34% (156.1m / 955.6m)
NOPAT = 2.46b (EBIT 2.95b * (1 - 16.34%))
Current Ratio = 4.87 (Total Current Assets 9.78b / Total Current Liabilities 2.01b)
Debt / Equity = 0.02 (Debt 302.8m / totalStockholderEquity, last quarter 17.82b)
Debt / EBITDA = -1.55 (Net Debt -5.63b / EBITDA 3.62b)
Debt / FCF = -2.26 (Net Debt -5.63b / FCF TTM 2.49b)
Total Stockholder Equity = 17.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.47% (Net Income 2.86b / Total Assets 20.63b)
RoE = 16.39% (Net Income TTM 2.86b / Total Stockholder Equity 17.43b)
RoCE = 16.65% (EBIT 2.95b / Capital Employed (Equity 17.43b + L.T.Debt 263.8m))
RoIC = 14.14% (NOPAT 2.46b / Invested Capital 17.43b)
WACC = 9.24% (E(160.56b)/V(160.86b) * Re(9.21%) + D(302.8m)/V(160.86b) * Rd(29.85%) * (1-Tc(0.16)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.31%
[DCF] Terminal Value 74.66% ; FCFF base≈2.02b ; Y1≈2.09b ; Y5≈2.40b
[DCF] Fair Price = 111.7 (EV 34.05b - Net Debt -5.63b = Equity 39.68b / Shares 355.2m; r=9.24% [WACC]; 5y FCF grow 4.02% → 3.0% )
EPS Correlation: 14.93 | EPS CAGR: -43.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.06 | Revenue CAGR: 19.11% | SUE: 2.17 | # QB: 6
EPS next Quarter (2026-06-30): EPS=2.48 | Chg7d=-0.000 | Chg30d=+0.005 | Revisions Net=+5 | Analysts=26
EPS current Year (2026-12-31): EPS=10.03 | Chg7d=-0.002 | Chg30d=+0.013 | Revisions Net=+3 | Growth EPS=+12.3% | Growth Revenue=+14.6%
EPS next Year (2027-12-31): EPS=11.44 | Chg7d=-0.011 | Chg30d=+0.003 | Revisions Net=+3 | Growth EPS=+14.1% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: +1.00 (5 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.5% (Discount Rate 9.2% - Earnings Yield 1.7%)
[Growth] Growth Spread = +7.1% (Analyst 14.6% - Implied 7.5%)
External Resources
Dataroma Stockcircle